vismodegib (Erivedge)
Jump to navigation
Jump to search
Indications
- basal cell carcinoma
- locally advanced or metastasized
- surgery or radiation is not an option
Contraindications
Dosage
Adverse effects
- muscle spasms
- alopecia
- weight loss
- nausea/vomiting
- diarrhea, constipation
- anorexia
- dysgeusia
- fatigue
Mechanism of action
- inhibits Hedgehog pathway
Notes
- maintenane4 of remission in those with complete response after cessation of drug
- marketed by Genentech
More general terms
Additional terms
References
- ↑ FDA NEWS RELEASE: Jan. 30, 2012 FDA approves new treatment for most common type of skin cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289545.htm
- ↑ Herms F, Lambet J, Grob JJ et al Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients. J Clin Oncol. 2019 Dec 1;37(34):3275-3282 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31609670 https://ascopubs.org/doi/abs/10.1200/JCO.18.00794?journalCode=jco